Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia

Part of paid clinical trials in Bellevue, Washington.

Sponsor
Bellevue Dermatology
Study ID
NCT03422640
Phase
PHASE4
Status
Unknown

Conditions

  • Frontal Fibrosing Alopecia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Open label treatment with apremilast

Study Details

This is open label single side study involvement 20 patient treated with Apremilast. Each enrolled patient may be evaluated at by a dermatologist using the Lichen Planopilaris Activity Index and Frontal Fibrosing Alopecia Index. Other measures include physician global assessment, dermatology quality of life and patients analogue score for pruritus. Pt will have visits at Week 0,2,4,8,12,16,20,24

Key Dates

First listed
Feb 6, 2018
Start date
Jul 12, 2018
Status verified
Jul 2018
Primary completion
Jan 31, 2019
Completion
Jan 31, 2019

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm with apremilast
    Open label arm treating frontal fibrosing alopecia with apremilast

Primary Outcome Measure

Lichen Planopilaris index [ Time Frame: Week 0 to 24, patient visit week0,2,4,8,12,16,20,24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Bellevue DermatologyBellevueWashington98004
Clive M Liu, MD
[email protected]
425-455-2275

Find similar trials in Bellevue, WA

By research site
Bellevue Dermatology· Bellevue, WA

Related Studies